EMERYVILLE, Calif., June 6, 2012 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE AMEX:NBY) today announced successful completion of an End-of-Phase 2a meeting with the Food and Drug Administration (FDA) regarding the Company's NVC-422 program for treating impetigo, a highly contagious skin infection affecting millions of children and adults worldwide. During the meeting, the FDA provided guidance related to the proposed study protocol and statistical analysis plan, as well as the overall development plan. This valuable guidance is being incorporated into the Phase 2b protocol and analysis plan thereby enhancing the design of study. Implementation of the phase 2b program with NovaBay's partner Galderma S.A. is actively progressing following the successful meeting with FDA.
